Extended Data Table 1 Baseline characteristics and survival outcomes of patients in the ctDNA cohort vs. the non-evaluated patients in the SONIA trial

From: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial

  1. AI: aromatase inhibitor, CDK4/6i: CDK4/6 inhibitor, IQR: interquartile range, ECOG: Eastern Cooperative Oncology Group, NST: invasive carcinoma ‘no special type’ includes large-cell carcinoma, adenocarcinoma and ductal carcinoma.
  2. a De novo metastatic disease (referred to as synchronous disease) is defined as the presence of metastatic disease at the time of initial diagnosis (within 6 months).
  3. b Percentage does not equal 100% as the result of rounding.
  4. c Statistical test: the Chi-square test was used for categorical variables (1) and a Welch two-sample t-test was performed for continuous variables (2). A log-rank test (3) was used to compare median survival outcomes. All reported p-values are two-sided.
Back to article page